The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

Diabetologia

Volumn 46, Issue 1, 2003, Pages 3-19

  Kahn, S E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Adiponectin; Aging; Amylin; Amyloid; Intra abdominal fat; Islet amyloid polypeptide; Leptin; Polycystic ovary syndrome; Proinsulin; Subcutaneous fat

Indexed keywords

ACARBOSE; ADIPONECTIN; AMYLIN; ANTIDIABETIC AGENT; CORTICOSTEROID; GLUCOSE; GROWTH HORMONE; HEMOGLOBIN A1C; INSULIN; ISOPRENALINE; LEPTIN; METFORMIN; NATEGLINIDE; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PRAVASTATIN; RAMIPRIL; ROSIGLITAZONE; TOLBUTAMIDE; TROGLITAZONE;

AGING; BODY FAT; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DISEASE ASSOCIATION; ETHNOLOGY; EXERCISE; FEEDBACK SYSTEM; HEREDITY; HIGH RISK POPULATION; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PATHOPHYSIOLOGY; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PUBLICATION; REVIEW; SUBCUTANEOUS FAT;

EID: 0037283601     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-002-1009-0     Document Type: Review

References (167)

1. Kahn SE, Porte D, Jr (1996) Pathophysiology of type II diabetes mellitus. In: Porte D Jr, Sherwin RS (eds) Diabetes mellitus. Appleton and Lange, Stamford, pp 487-512
2. DeFronzo RA, Ferrannini E (1991) Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 14:173-194
3. Kruszynska YT, Olefsky JM (1996) Cellular and molecular mechanisms of non-insulin dependent diabetes mellitus. J Investig Med 44:413-428
4. Porte D Jr (1991) β-cells in type II diabetes mellitus. Diabetes 40:166-180
5. Mitrakou A, Kelley D, Mokan M et al. (1992) Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 326:22-29
6. Kahn SE (2001) The importance of beta-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab 86:4047-4058
7. National Heart Lung and Blood Institute (1998) Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. Obes Res 6 [Suppl 2]:51S-209S
8. King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21:1414-1431
9. Olefsky J, Farquhar JW, Reaven G (1973) Relationship between fasting plasma insulin level and resistance to insulin-mediated glucose uptake in normal and diabetic subjects. Diabetes 22:507-513
10. Beard JC, Ward WK, Halter JB, Wallum BJ, Porte D Jr (1987) Relationship of islet function to insulin action in human obesity. J Clin Endocrinol Metab 65:59-64
11. Rosenbloom AL, Joe JR, Young RS, Winter WE (1999) Emerging epidemic of type 2 diabetes in youth. Diabetes Care 22:345-354
12. Dabelea D, Pettitt DJ, Jones KL, Arslanian SA (1999) Type 2 diabetes mellitus in minority children and adolescents. An emerging problem. Endocrinol Metab Clin North Am 28:709-729
13. Sinha R, Fisch G, Teague B et al. (2002) Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346:802-810
14. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853
15. Turner RC, Cull CA, Frighi V, Holman RR (1999) Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 281:2005-2012
16. The Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
17. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC (1998) UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 15:297-303
18. Holman RR (1998) Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. Diabetes Res Clin Pract 40 [Suppl]:S21-S25
19. Virkamaki A, Ueki K, Kahn CR (1999) Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance. J Clin Invest 103:931-943
20. Barroso I, Gurnell M, Crowley VE et al. (1999) Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 402:880-883
21. DeFronzo RA (1979) Glucose intolerance of aging. Evidence for tissue insensitivity to insulin. Diabetes 28:1095-1101
22. Chen M, Bergman RN, Pacini G, Porte D Jr (1985) Pathogenesis of age-related glucose intolerance in man: insulin resistance and decreased β-cell function. J Clin Endocrinol Metab 60:13-20
23. Prigeon RL, Kahn SE, Porte D Jr. (1995) Changes in insulin sensitivity, glucose effectiveness, and B-cell function in regularly exercising subjects. Metabolism 44:1259-1263
24. Kahn SE, Larson VG, Beard JC et al. (1990) Effect of exercise on insulin action, glucose tolerance and insulin secretion in aging. Am J Physiol 258:E937-E943
25. Chen M, Halter JB, Porte D Jr (1987) The role of dietary carbohydrate in the decreased glucose tolerance of the elderly. J Am Geriatr Soc 35:417-424
26. Beard JC, Halter JB, Best JD, Pfeifer MA, Porte D Jr (1984) Dexamethasone-induced insulin resistance enhances B-cell responsiveness to glucose level in normal men. Am J Physiol 247:E592-E596
27. Rizza RA, Mandarino LJ, Gerich JE (1982) Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 31:663-669
28. Kahn SE, Beard JC, Schwartz MW et al. (1989) Increased β-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 38:562-568
29. Kolterman OG, Insel J, Saekow M, Olefsky JM (1980) Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. J Clin Invest 65:1272-1284
30. Lillioja S, Bogardus C (1988) Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 4:517-540
31. Bjorntorp P (1993) Visceral obesity: a "civilization syndrome". Obes Res 1:206-222
32. Peiris AN, Mueller RA, Smith GA, Struve MF, Kissebah AH (1986) Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest 78:1648-1657
33. Pouliot MC, Despres JP, Nadeau A et al. (1992) Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41:826-834
34. Peiris AN, Sothmann MS, Hennes MI et al. (1989) Relative contribution of obesity and body fat distribution to alterations in glucose insulin homeostasis: predictive values of selected indices in premenopausal women. Am J Clin Nutr 49:758-764
35. Fujimoto WY, Abbate SL, Kahn SE, Hokanson JE, Brunzell JD (1994) The visceral adiposity syndrome in Japanese-American men. Obes Res 2:364-371
36. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM (1995) Relationships of generalized and regional adiposity to insulin sensitivity in men. J Clin Invest 96:88-98
37. Goodpaster BH, Kelley DE, Wing RR, Meier A, Thaete FL (1999) Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes 48:839-847
38. Cnop M, Landchild MJ, Vidal J et al. (2002) The concurrent accumulation of intra-abdominal and subcutaneous fat explains the association between insulin resistance and plasma leptin concentrations: distinct metabolic effects of two fat compartments. Diabetes 51:1005-1015
39. Taylor SI, Cama A, Accili D et al. (1992) Mutations in the insulin receptor gene. Endocr Rev 13:566-595
40. Xia J, Scherer SW, Cohen PT et al. (1998) A common variant in PPP1R3 associated with insulin resistance and type 2 diabetes. Diabetes 47:1519-1524
41. Hegele RA, Harris SB, Zinman B et al. (1998) Variation in the AU(AT)-rich element within the 3′-untranslated region of PPP1R3 is associated with variation in plasma glucose in aboriginal Canadians. J Clin Endocrinol Metab 83:3980-3983
42. Hansen L, Hansen T, Vestergaard H et al. (1995) A widespread amino acid polymorphism at codon 905 of the glycogen-associated regulatory subunit of protein phosphatase-1 is associated with insulin resistance and hypersecretion of insulin. Hum Mol Genet 4:1313-1320
43. Hansen L, Reneland R, Berglund L et al. (2000) Polymorphism in the glycogen-associated regulatory subunit of type 1 protein phosphatase (PPP1R3) gene and insulin sensitivity. Diabetes 49:298-301
44. Stumvoll M, Tschritter O, Fritsche A et al. (2002) Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes 51:37-41
45. Hasstedt SJ, Ren QF, Teng K, Elbein SC (2001) Effect of the peroxisome proliferator-activated receptor-gamma 2 pro(12)ala variant on obesity, glucose homeostasis, and blood pressure in members of familial type 2 diabetic kindreds. J Clin Endocrinol Metab 86:536-541
46. Deeb SS, Fajas L, Nemoto M et al. (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287
47. Altshuler D, Hirschhorn JN, Klannemark M et al. (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80
48. Horton ES (1986) Exercise and physical training: effects on insulin sensitivity and glucose metabolism. Diabetes Metab Rev 2:1-17
49. Chen M, Bergman RN, Porte D Jr (1988) Insulin resistance and β-cell dysfunction in aging: the importance of dietary carbohydrate. J Clin Endocrinol Metab 67:951-957
50. Brunzell JD, Lerner RL, Hazzard WR, Porte D Jr, Bierman EL (1971) Improved glucose tolerance with high carbohydrate feeding in mild diabetes. N Engl J Med 284:521-524
51. Despres JP, Moorjani S, Lupien PJ, Tremblay A, Nadeau A, Bouchard C (1990) Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis 10:497-511
52. Peiris AN, Sothmann MS, Hoffmann RG et al. (1989) Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med 110:867-872
53. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Adams-Huet B, Grundy SM (1996) Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes 45:1684-1693
54. Kahn SE, Prigeon RL, McCulloch DK et al. (1993) Quantification of the relationship between insulin sensitivity and B-cell function in human subjects. Evidence for a hyperbolic function. Diabetes 42:1663-1672
55. Cnop M, Havel PJ, Utzschneider KM et al. (2002) Gender-based differences in adiponectin and leptin levels are related to differences in body fat distribution. Diabetes 50 [Suppl 2]:A404 (Abstract)
56. Matsuzawa Y, Funahashi T, Nakamura T (1999) Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann NY Acad Sci 892:146-154
57. Weyer C, Funahashi T, Tanaka S et al. (2001) Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935
58. Hotta K, Funahashi T, Arita Y et al. (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599
59. Couillard C, Mauriege P, Prud'homme D et al. (1997) Plasma leptin concentrations: gender differences and associations with metabolic risk factors for cardiovascular disease. Diabetologia 40:1178-1184
60. Schwartz RS, Shuman WP, Bradbury VL et al. (1990) Body fat distribution in healthy young and older men. J Gerontol 45:M181-M185
61. Purnell JQ, Kahn SE, Albers JJ, Nevin DN, Brunzell JD, Schwartz RS (2000) Effect of weight loss with reduction of intra-abdominal fat on lipid metabolism in older men. J Clin Endocrinol Metab 85:977-982
62. Schwartz RS, Shuman WP, Larson V et al. (1991) The effect of intensive endurance exercise training on body fat distribution in young and older men. Metabolism 40:545-551
63. Auwerx J (1999) PPARgamma, the ultimate thrifty gene. Diabetologia 42:1033-1049
64. Hirose H, Kawai T, Yamamoto Y et al. (2002) Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51:314-317
65. Mori Y, Murakawa Y, Okada K et al. (1999) Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 22:908-912
66. Steppan CM, Bailey ST, Bhat S et al. (2001) The hormone resistin links obesity to diabetes. Nature 409:307-312
67. Yang WS, Jeng CY, Wu TJ et al. (2002) Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 25:376-380
68. Perley MJ, Kipnis DM (1967) Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest 46:1954-1962
69. Bagdade JD, Bierman EL, Porte D Jr (1967) The significance of basal insulin levels in the evaluation of the insulin response to glucose in diabetic and nondiabetic subjects. J Clin Invest 46:1549-1557
70. Brunzell JD, Robertson RP, Lerner RL et al. (1976) Relationships between fasting plasma glucose levels and insulin secretion during intravenous glucose tolerance tests. J Clin Endocrinol Metab 42:222-229
71. Ward WK, Bolgiano DC, McKnight B, Halter JB, Porte D Jr (1984) Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. J Clin Invest 74:1318-1328
72. Halter JB, Porte D Jr (1978) Mechanisms of impaired acute insulin release in adult onset diabetes: studies with isoproterenol and secretin. J Clin Endocrinol Metab 46:952-960
73. Varsano-Aharon N, Echemendia E, Yalow RS, Berson SA (1970) Early insulin responses to glucose and to tolbutamide in maturity-onset diabetes. Metabolism 19:409-417
74. O'Rahilly S, Turner RC, Matthews DR (1988) Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 318:1225-1230
75. Porksen N (2002) The in vivo regulation of pulsatile insulin secretion. Diabetologia 45:3-20
76. Polonsky KS, Given BD, Hirsch LJ et al. (1988) Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318:1231-1239
77. Mako ME, Starr JI, Rubenstein AH (1977) Circulating proinsulin in patients with maturity-onset diabetes. Am J Med 63:865-869
78. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, Porte D Jr (1987) Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and experimental insulin resistance. Diabetologia 30:698-702
79. Yoshioka N, Kuzuya T, Matsuda A, Taniguchi M, Iwamoto Y (1988) Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 31:355-360
80. Temple RC, Clark PM, Nagi DK, Schneider AE, Yudkin JS, Hales CN (1990) Radioimmunoassay may overestimate insulin in non-insulin-dependent diabetics. Clin Endocrinol (Oxf) 32:689-693
81. Saad MF, Kahn SE, Nelson RG et al. (1990) Disproportionately elevated proinsulin in Pima Indians with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 70:1247-1253
82. Kahn SE, Leonetti DL, Prigeon RL, Bergstrom RW, Fujimoto WY (1995) Relationship of proinsulin and insulin with noninsulin-dependent diabetes mellitus and coronary heart disease in Japanese American men: impact of obesity. J Clin Endocrinol Metab 80:1399-1406
83. Kahn SE, Halban PA (1997) Release of incompletely processed proinsulin is the cause of the disproportionate proinsulinemia of NIDDM. Diabetes 46:1725-1732
84. Sanke T, Hanabusa T, Nakano Y et al. (1991) Plasma islet amyloid polypeptide (amylin) levels and their responses to oral glucose in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34:129-132
85. Ludvik B, Lell B, Hartter E, Schnack C, Prager R (1991) Decrease of stimulated amylin release precedes impairment of insulin secretion in type II diabetes. Diabetes 40:1615-1619
86. Enoki S, Mitsukawa T, Takemura J et al. (1992) Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15:97-102
87. Kahn SE, Verchere CB, Andrikopoulos S et al. (1998) Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47:640-645
88. Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group (2002) β-cell function is the major determinant of oral glucose tolerance in four ethnic groups in the United States. Diabetes 51:2170-2178
89. Yalow RS, Berson SA (1960) Plasma insulin concentrations in nondiabetic and early diabetic subjects: determinations by a new sensitive immunoassay technic. Diabetes 9:254-260
90. Ward WK, Beard JC, Halter JB, Pfeifer MA, Porte D Jr (1984) Pathophysiology of insulin secretion in non-insulin-dependent diabetes mellitus. Diabetes Care 7:491-502
91. Karam JH, Grodsky GM, Forsham PH (1963) Excessive insulin response to glucose in obese subjects as measured by immunochemical assay. Diabetes 12:197-204
92. Bagdade JD, Porte D Jr, Brunzell JD, Bierman EL (1974) Basal and stimulated hyperinsulinism: reversible metabolic sequelae of obesity. J Lab Clin Med 83:563-569
93. Bergman RN, Phillips LS, Cobelli C (1981) Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and β-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 68:1456-1467
94. Clausen JO, Borch-Johnsen K, Ibsen H et al. (1996) Insulin sensitivity index, acute insulin response, and glucose effectiveness in a population-based sample of 380 young healthy Caucasians. Analysis of the impact of gender, body fat, physical fitness, and life-style factors. J Clin Invest 98:1195-1209
95. Weyer C, Bogardus C, Mott DM, Pratley RE (1999) The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 104:787-794
96. Ehrmann DA, Sturis J, Byrne MM, Karrison T, Rosenfield RL, Polonsky KS (1995) Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus. J Clin Invest 96:520-527
97. Kahn SE (1996) Regulation of B-cell function in vivo: from health to disease. Diabetes Rev 4:372-389
98. Elbein SC, Wegner K, Kahn SE (2000) Reduced β-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. Diabetes Care 23:221-227
99. Ward WK, Johnston CLW, Beard JC, Benedetti TJ, Halter JB, Porte D Jr (1985) Insulin resistance and impaired insulin secretion in subjects with histories of gestational diabetes mellitus. Diabetes 34:861-869
100. Ryan EA, Imes S, Liu D et al. (1995). Defects in insulin secretion and action in women with a history of gestational diabetes. Diabetes 44:506-512
101. Buchanan TA, Xiang AH, Kjos SL, Trigo E, Lee WP, Peters RK (1999) Antepartum predictors of the development of type 2 diabetes in Latino women 11-26 months after pregnancies complicated by gestational diabetes. Diabetes 48:2430-2436
102. Dunaif A, Finegood DT (1996) Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81:942-947
103. Kahn SE, Larson VG, Schwartz RS et al. (1992) Exercise training delineates the importance of B-cell dysfunction to the glucose intolerance of human aging. J Clin Endocrinol Metab 74:1336-1342
104. Larsson H, Ahren B (1996) Islet dysfunction in obese women with impaired glucose tolerance. Metabolism 45:502-509
105. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS (1997) Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537
106. Knowles NG, Landchild MA, Fujimoto WY, Kahn SE (2002) Insulin and amylin release are both diminished in first-degree relatives of subjects with type 2 diabetes. Diabetes Care 25:292-297
107. Elbein SC, Hasstedt SJ, Wegner K, Kahn SE (1999) Heritability of pancreatic beta-cell function among nondiabetic members of Caucasian familial type 2 diabetic kindreds. J Clin Endocrinol Metab 84:1398-1403
108. Haffner S, Stern M, Hazuda H, Mitchell B, Patterson J (1988) Increased insulin concentrations in nondiabetic offspring of diabetic parents. N Engl J Med 319:1297-1301
109. Lillioja S, Mott DM, Howard BV et al. (1988) Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217-1225
110. Warram JH, Martin BC, Krolewski AS, Soeldner JS, Kahn CR (1990) Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 113:909-915
111. Martin BL, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925-929
112. Eriksson J, Franssila Kallunki A, Ekstrand A et al. (1989) Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. N Engl J Med 321:337-343
113. Lillioja S, Mott DM, Spraul M et al. (1993) Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N Engl J Med 329:1988-1992
114. Ferrannini E (1998) Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 19:477-490
115. Lukinius A, Wilander E, Westermark GT, Engstrom U, Westermark P (1989) Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 32:240-244
116. Kahn SE, D'Alessio DA, Schwartz MW et al. (1990) Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39:634-638
117. Kahn SE, Fujimoto WY, D'Alessio DA, Ensinck JW, Porte D Jr (1991) Glucose stimulates and potentiates islet amyloid polypeptide secretion by the B-cell. Horm Metab Res 23:577-580
118. Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE (1998) Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol 275:E785-E791
119. Larsson H, Ahren B (1995) Effects of arginine on the secretion of insulin and islet amyloid polypeptide in humans. Pancreas 11:201-205
120. Landchild MJ, Knowles NG, Yao Q et al. (2000) Increased β-cell secretory demand is not the simple explanation for inefficient proinsulin processing and islet amyloid formation in type 2 diabetes. J Investig Med 48:21A (Abstract)
121. Pimenta W, Korytkowski M, Mitrakou A et al. (1995) Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA 273:1855-1861
122. Schmitz O, Porksen N, Nyholm B et al. (1997) Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. Am J Physiol 272:E218-E226
123. Larsson H, Ahren B (1996) Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 39:1099-1107
124. O'Meara NM, Sturis J, Van Cauter E, Polonsky KS (1993) Lack of control by glucose of ultradian insulin secretory oscillations in impaired glucose tolerance and in non-insulin-dependent diabetes mellitus. J Clin Invest 92:262-271
125. Phillips DI, Clark PM, Hales CN, Osmond C (1994) Understanding oral glucose tolerance: comparison of glucose or insulin measurements during the oral glucose tolerance test with specific measurements of insulin resistance and insulin secretion. Diabet Med 11:286-292
126. Kelley D, Mokan M, Veneman T (1994) Impaired post-prandial glucose utilization in non-insulin-dependent diabetes mellitus. Metabolism 43:1549-1557
127. American Diabetes Association (1997) Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197
128. Clark A, Saad MF, Nezzer T et al. (1990) Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33:285-289
129. Kahn SE, Andrikopoulos S, Verchere CB (1999) Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48:241-253
130. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD, Johnson KH (1987) Amyloid fibrils in human insulinoma and islets of Langerhans of the diabetic cat are derived from a neuropeptide-like protein also present in normal islets. Proc Natl Acad Sci USA 84:3881-3885
131. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, Reid KBM (1987) Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84:8628-8632
132. Westermark P, Engstrom U, Johnson KH, Westermark GT, Betsholtz C (1990) Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87:5036-5040
133. Verchere CB, D'Alessio DA, Palmiter RD et al. (1996) Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93:3492-3496
134. Soeller WC, Janson J, Hart SE et al. (1998) Islet amyloid-associated diabetes in obese Avy/a mice expressing human islet amyloid polypeptide. Diabetes 47:743-750
135. Höppener JW, Oosterwijk C, Nieuwenhuis MG et al. (1999) Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42:427-434
136. Howard CF Jr (1986) Longitudinal studies on the development of diabetes in individual Macaca nigra. Diabetologia 29:301-306
137. Wang F, Hull RL, Vidal J, Cnop M, Kahn SE (2001) Islet amyloid develops diffusely throughout the pancreas before becoming severe and replacing endocrine cells. Diabetes 50:2514-2520
138. Yki-Järvinen H (1992) Glucose toxicity. Endocr Rev 13:415-431
139. Robertson RP, Olson LK, Zhang HJ (1994) Differentiating glucose toxicity from glucose desensitization: a new message from the insulin gene. Diabetes 43:1085-1089
140. Garvey WT, Olefsky JM, Griffen J, Hamman RF, Kolterman OG (1985) The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes 34:222-234
141. Kahn SE, Bergman RN, Schwartz MW, Taborsky GJ Jr, Porte D Jr (1992) Short-term hyperglycemia and hyperinsulinemia improve insulin action but do not alter glucose action in normal humans. Am J Physiol 262:E518-E523
142. Ward WK, Halter JB, Beard JC, Porte D Jr (1984) Adaptation of B and A cell function during prolonged glucose infusion in human subjects. Am J Physiol 246:E405-E411
143. Byrne MM, Sturis J, Polonsky KS (1995) Insulin secretion and clearance during low-dose graded glucose infusion. Am J Physiol 268:E21-E27
144. Hartling SG, Røder ME, Dinesen B, Binder C (1996) Proinsulin, C-peptide, and insulin in normal subjects during an 8-h hyperglycemic clamp. Eur J Endocrinol 134:197-200
145. Reaven GM, Hollenbeck C, Jeng CY, Wu MS, Chen YD (1988) Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37:1020-1024
146. Thompson AL, Lim-Fraser MY, Kraegen EW, Cooney GJ (2000) Effects of individual fatty acids on glucose uptake and glycogen synthesis in soleus muscle in vitro. Am J Physiol Endocrinol Metab 279:E577-E584
147. Zhou YP, Grill VE (1994) Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle. J Clin Invest 93:870-876
148. Zhou YP, Grill V (1995) Long term exposure to fatty acids and ketones inhibits B-cell functions in human pancreatic islets of Langerhans. J Clin Endocrinol Metab 80:1584-1590
149. Boden G (1997) Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10
150. Roden M, Price TB, Perseghin G et al. (1996) Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97:2859-2865
151. Griffin ME, Marcucci MJ, Cline GW et al. (1999) Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade. Diabetes 48:1270-1274
152. Boden G, Chen X, Rosner J, Barton M (1995) Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 44:1239-1242
153. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF (1999) Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 276:E1055-E1066
154. Paolisso G, Gambardella A, Amato L et al. (1995) Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 38:1295-1299
155. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG (2000) Central nervous system control of food intake. Nature 404:661-671
156. Porte D Jr, Seeley RJ, Woods SC, Baskin DG, Figlewicz DP, Schwartz MW (1998) Obesity, diabetes and the central nervous system. Diabetologia 41:863-881
157. Eriksson K-F, Lindgarde F (1991) Prevention of Type 2 (non-insulin-dependent) diabetes mellitus by diet and physical exercise: the 6-year Malmo: feasibility study. Diabetologia 34:891-898
158. Pan XR, Li GW, Hu YH et al. (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544
159. Tuomilehto J, Lindstrom J, Eriksson JG et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350
160. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359:2072-2077
161. Buchanan TA, Xiang AH, Peters RK et al. (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high- risk hispanic women. Diabetes 51:2796-2803
162. The Diabetes Prevention Program Research Group (1999) The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 22:623-634
163. Yusuf S, Gerstein H, Hoogwerf B et al. (2001) Ramipril and the development of diabetes. JAMA 286:1882-1885
164. Haffner S, Holman R, Califf R, McMurray J, Pehcer E (2002) Targeting post-prandial hyperglycemia to prevent type 2 diabetes: Rationale and design of the NAVIGATOR trial. Diabetologia 45 [Suppl 2]:A106 (Abstract)
165. Freeman DJ, Norrie J, Sattar N et al. (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103:357-362
166. Welch S, Gebhart SSP, Bergman RN, Phillips LS (1990) Minimal model analysis of intravenous glucose tolerance test-derived insulin sensitivity in diabetic subjects. J Clin Endocrinol Metab 71:1508-1518
167. Vidal J, Kahn SE (2001) Regulation of insulin secretion in vivo. In: Lowe WL Jr (ed.) Genetics of Diabetes Mellitus. Kluwer, Stamford, pp 109-131